RedHill Biopharma Ltd. (NASDAQ: RDHL) confirmed that it has regained compliance with Nasdaq’s stockholders’ equity requirement, following a notification received on November 26, 2025. The company’s stockholders’ equity now exceeds the $2.5 million threshold that is required for continued Nasdaq listing.
The compliance achievement follows a period of financial restructuring that saw RedHill’s equity fall below the minimum in April 2025, when a deficit of $4.683 million triggered a Nasdaq deficiency notice. Since then, the company has implemented a series of cost‑control measures and secured additional capital through an at‑the‑market offering, raising its equity to $3.2 million as of the latest filing.
Restoring full listing status removes the risk of delisting and preserves access to capital markets, a critical factor for a company that is transitioning to a commercial‑stage gastrointestinal business. The move also supports RedHill’s broader strategy of reducing reliance on external financing, as evidenced by its recent legal victory against Kukbo Co. Ltd., which awarded the company over $10.5 million in damages.
RedHill’s financial performance in the first half of 2025 underscores the effectiveness of its operational focus. Net revenues rose 59% to $4.1 million, driven largely by the Talicia co‑commercialization partnership with Cumberland Pharmaceuticals, which contributed $3.8 million. Gross profit doubled to $2.5 million, reflecting improved pricing power and a favorable product mix, while the company reduced its cash burn by 19% compared to the prior year.
Management highlighted that the regained equity position and the company’s cash‑flow trajectory position RedHill to pursue further growth initiatives without the need for additional debt. CEO Dror Ben‑Asher noted that “maintaining Nasdaq listing status is a cornerstone of our financial discipline strategy, and the current equity level gives us the flexibility to invest in high‑return opportunities while safeguarding shareholder value.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.